Pediatric Vaccines Market Size, Share, and Trends 2024 to 2033

Pediatric Vaccines Market Size and Growth

The global pediatric vaccines market size was USD 59.13 billion in 2023, calculated at USD 62.67 billion in 2024 and is expected to reach around USD 105.69 billion by 2033, expanding at a CAGR of 5.98% from 2024 to 2033. Vaccines' ability to prevent illness can contribute to the overall health of pediatric populations, which significantly grows the pediatric vaccines market.

Pediatric Vaccines Market Key Takeaways

• The North America pediatric vaccines market size reached USD 21.88 billion in 2023 and is expected to attain around USD 39.63 billion by 2033, poised to grow at a CAGR of 6.12% between 2024 and 2033.
• North America dominated the market with the largest revenue share in 2023.
• By type, the monovalent segment has held a major revenue share of 60% in 2023.
• By type, the multivalent segment is expected to expand significantly in the market during the forecast period.
• By technology, the subunit, recombinant, polysaccharide, & conjugate vaccines segment led the market in 2023.
• By technology, the inactivated vaccines segment is expected to grow at a rapid pace in the market during the forecast period.
• By indication, the pneumococcal disease segment dominated the market in 2023.
• By indication, the influenza segment is expected to grow at the highest CAGR in the market during the forecast period.

U.S. Pediatric Vaccines Market Size and Growth 2024 to 2033

The U.S. pediatric vaccines market size was exhibited at USD 16.41 billion in 2023 and is projected to be worth around USD 29.92 billion by 2033, poised to grow at a CAGR of 6.19% from 2024 to 2033.

North America dominated the pediatric vaccines market in 2023 and is expected to sustain this dominance throughout the forecast period. The economies of North America, and especially the United States, are among the biggest and most dynamic in the world. The demand is driven across a number of industries by this economic strength, which translates into enormous buying power and market size. The area has significant research and development (R&D) skills and is a global leader in technological innovation. This encourages ongoing improvements in infrastructure and technology, especially in industries like IT, healthcare, automotive, and aerospace.

North America boasts a sophisticated infrastructure, encompassing cutting-edge digital infrastructure, utilities, and transportation networks. This makes it easier for products and services to be produced, distributed, and consumed efficiently. The region's competitive advantage is preserved by large investments in R&D across industries. As a result, innovative goods and services are produced, propelling the expansion of the pediatric vaccines market.

Market Overview

The pediatric vaccines market refers to the drugs and vaccines that are used to treat diseases of infants, children, and adolescents from birth to the age of 18. The word pediatric is derived from a Greek word that means pediatric and is ‘healer of children.’ There are some emergency medical drugs and vaccines used in situations of life and death.

The pediatric vaccines market is fragmented with multiple small-scale and large-scale players, such as Serum Institute of India Pvt. Ltd., Sanofi Aventis, CSL Limited, AstraZeneca Plc., Merck & Co., Inc., GlaxoSmithKline Plc., Pfizer Inc., Emergent BioSolutions Inc., Novavax, Inc., Johnson & Johnson.

Pediatric Vaccines Market Growth Factors

• Government agencies and healthcare organizations continuously promote strategies to combat infectious diseases in children, which boosts the pediatric vaccine market.
• Governments in some countries recognize the importance of child health and are implementing various initiatives to improve healthcare infrastructure, which raises the demand for the pediatric vaccines market.
• The collaboration between the companies helps to share a financial burden and regulatory compliance and also helps in technological and data sharing. It also helps in research and development and advancement in pediatric vaccines and can grow the pediatric vaccines market.
• The vaccination program and funding for research and development in pediatric drugs and vaccine manufacturing companies.

Pediatric Vaccines Market Scope

Pediatric Vaccines Market Dynamics

Drivers

Rising prevalence of pediatric diseases

The prevalence of pediatric diseases plays an important role in boosting the pediatric vaccine market. Pediatric diseases are diagnosed in infants, children, and adolescents from birth to the age of 18. The more the increase in the rate of infants, the more the chances of the rising prevalence of pediatric diseases.

Rising awareness of child health

The rising awareness of child health significantly grows the pediatric vaccines market. There are some initiatives that raise awareness of child health. For instance, the National Center for Healthy Safe Children offers resources and technical assistance to states, tribes, territories, and local communities to promote the overall well-being of children, youth, and their families. The rising awareness of child health includes vaccination programs and funding for research and development in pediatric drugs and vaccine manufacturing companies.

Restraint

Limited medical coverage and healthcare services in low and middle-income countries

The limited medical coverage and healthcare services in low and middle-income countries can negatively affect the pediatric vaccine market. Good medical and healthcare services for a healthy and quality life are an essential element of human rights. Yet more than half of pediatrics can’t get proper medication treatment for pediatric vaccines. So, the limited medical coverage and healthcare services in low and middle-income countries can negatively affect the pediatric vaccines market.

Opportunity

Government and healthcare initiatives

The government and healthcare initiatives can be the opportunity to boost the pediatric vaccines market. Government agencies and healthcare organizations continuously promote strategies to combat infectious diseases in children. This initiative includes vaccination campaigns, educational programs for the parents of children, and efforts to improve healthcare infrastructure.

• In March 2024, the state government installed 43,000 booths in all primary health centers, government hospitals, integrated child development scheme centers, and other places, which are important for the nationwide pulse polio immunization campaign, which was inaugurated by the CM.

Type Insights

The monovalent segment held the dominant share of the pediatric vaccines market in 2023. The vaccines that are monovalent, targeting just one pathogen or strain, are easier to create and evaluate than those that are multivalent, targeting several pathogens. As a result, clinical trials and regulatory approval procedures have become less complicated. The monovalent vaccines have the ability to elicit a strong and targeted immune response by targeting just one pathogen. This is especially crucial for pathogens that are highly dangerous to populations of children.

In general, the safety profile of monovalent vaccines is well-established. When compared to vaccines that contain multiple antigens, the risk of adverse reactions is lower with fewer components. Targeted treatment is the best way to manage certain diseases. The introduction of monovalent vaccines, for example, can considerably lower the disease burden in children against a common and dangerous pathogen.

The multivalent segment is expected to expand significantly in the pediatric vaccines market during the forecast period. The number of injections required is decreased by multivalent vaccines, which offer protection against several pathogen strains or varieties in a single dose. For pediatric patients, who frequently need to receive multiple vaccinations, this is especially advantageous. It is easier for parents to follow vaccination recommendations and finish their children's immunization process when multiple vaccines are combined into a single injection. The families benefit from more convenience and a lighter load on healthcare systems when fewer injections are administered, and fewer trips to medical professionals result. This is especially crucial in environments with limited resources.

Technology Insights

The subunit, recombinant, polysaccharide, & conjugate vaccines segment led the pediatric vaccines market in 2023. The strong safety profiles of these vaccines are well-known. Comparatively speaking to whole-pathogen vaccines, they lower the risk of adverse reactions by utilizing only particular pathogen components (like proteins or sugars). The vaccines containing subunits, recombinants, polysaccharides, and conjugates are intended to provoke potent and focused immune reactions.

In particular, conjugate vaccines strengthen the immune response, particularly in newborns and early children, by attaching polysaccharide antigens to protein carriers. These vaccines work well against the pathogens that cause serious and prevalent childhood illnesses. Conjugate vaccines, for instance, are used to protect children against the bacteria Haemophilus influenzae type b (Hib) and pneumococcal infections, both of which can be fatal. Because of these vaccines' efficacy and safety, numerous national and international immunization programs give them top priority.

The inactivated vaccines segment is expected to grow at a rapid pace in the pediatric vaccines market during the forecast period. Vaccines that contain dead pathogens or inactivated vaccines have a good safety record. They are especially good for young children whose immune systems are still developing because they do not carry the risk of contracting the disease that they are intended to prevent. These vaccinations effectively protect against a range of diseases by inducing a robust immune response that rarely reverts to a virulent form. The improvements in vaccine technology and production processes have enhanced the efficacy and stability of inactivated vaccines. These developments have increased the likelihood that these vaccinations will be widely used in pediatric populations.

Indication Insights

The pneumococcal disease segment dominated the pediatric vaccines market in 2023. The bacterium Streptococcus pneumoniae, which causes pneumococcal disease, can cause pneumonia, meningitis, and sepsis, among other serious illnesses, especially in children. The demand for vaccines is fueled by the fact that parents and healthcare professionals are gravely concerned about them due to their potential severity and frequency. Pneumococcal vaccinations have proven to be very successful in stopping the spread of the bacteria and preventing disease.

The widespread inclusion of pneumococcal vaccines in pediatric vaccination schedules can be attributed in part to their efficacy. The children should receive routine vaccinations against pneumococcal disease, according to national and international health organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Pneumococcal vaccination awareness and uptake are raised by these recommendations.

The influenza segment is expected to grow at the highest CAGR in the pediatric vaccines market during the forecast period. The pediatric vaccine market is anticipated to see growth in the influenza segment as a result of efforts to increase vaccination coverage among pediatric populations in order to prevent the spread of influenza, improve vaccine development, and grow awareness of the significance of flu vaccination for children's health. Further propelling growth in this market will probably be the introduction of more practical and efficient vaccination options brought about by the continuous research and development in the field of pediatric vaccines.

Pediatric Vaccines Market Companies

• Serum Institute of India Pvt. Ltd.
• Sanofi Aventis
• CSL Limited
• AstraZeneca Plc.
• Merck & Co., Inc.
• GlaxoSmithKline Plc.
• Pfizer Inc.
• Emergent BioSolutions Inc.
• Novavax, Inc.
• Johnson & Johnson

Recent Developments

• In March 2024, Cadila Pharmaceuticals company launched an influenza vaccine, namely Cadiflu Tetra, which is used for both adults and children. Cadiflu Tetra is developed employing nano-sized particles. The vaccine mimics the external structure of the virus without containing intact genetic material.
• In March 2024, the FDA approved two measles vaccines, MMR II and Priorix, which are used in people ages 12 months and older. Kids ages 1 to 12 may also get the MMRV (measles, mumps and rubella, and varicella) or ProQuad vaccine, which also shields kids from chickenpox.
• In August 2023, AstraZeneca announced the launch of Selumetinib. Selumetinib is used to treat pediatric patients three years of age and older with neurofibromatosis type-1(NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

Segment Covered in the Report

By Type

• Monovalent
• Multivalent

By Technology

• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines

By Indication

• Varicella
• Human Papilloma Virus
• Measles, Mumps & Rubella
• Meningococcal Disease
• Pneumococcal Disease
• Polio
• Rotavirus
• Diphtheria, Pertussis & Tetanus
• Influenza
• Other Indications

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa